NEET MDS Synopsis
Pancreas
Physiology
The bulk of the pancreas is an exocrine gland secreting pancreatic fluid into the duodenum after a meal. However, scattered through the pancreas are several hundred thousand clusters of cells called islets of Langerhans. The islets are endocrine tissue containing four types of cells. In order of abundance, they are the:
beta cells, which secrete insulin and amylin;
alpha cells, which secrete glucagon;
delta cells, which secrete somatostatin, and
gamma cells, which secrete a polypeptide of unknown function.
Beta Cells
Beta cells secrete insulin in response to a rising level of blood sugar
Insulin affects many organs. It
stimulates skeletal muscle fibers to
take up glucose and convert it into glycogen;
take up amino acids from the blood and convert them into protein.
acts on liver cells
stimulating them to take up glucose from the blood and convert it into glycogen while
inhibiting production of the enzymes involved in breaking glycogen back down (glycogenolysis) and
inhibiting gluconeogenesis; that is, the conversion of fats and proteins into glucose.
acts on fat (adipose) cells to stimulate the uptake of glucose and the synthesis of fat.
acts on cells in the hypothalamus to reduce appetite.
Diabetes Mellitus
Diabetes mellitus is an endocrine disorder characterized by many signs and symptoms. Primary among these are:
a failure of the kidney to retain glucose .
a resulting increase in the volume of urine because of the osmotic effect of this glucose (it reduces the return of water to the blood).
There are three categories of diabetes mellitus:
Insulin-Dependent Diabetes Mellitus (IDDM) (Type 1) and
Non Insulin-Dependent Diabetes Mellitus (NIDDM)(Type 2)
Inherited Forms of Diabetes Mellitus
Insulin-Dependent Diabetes Mellitus (IDDM)
IDDM ( Type 1 diabetes)
is characterized by little or no circulating insulin;
most commonly appears in childhood.
It results from destruction of the beta cells of the islets.
The destruction results from a cell-mediated autoimmune attack against the beta cells.
What triggers this attack is still a mystery, although a prior viral infection may be the culprit.
Non Insulin-Dependent Diabetes Mellitus (NIDDM)
Many people develop diabetes mellitus without an accompanying drop in insulin levels In many cases, the problem appears to be a failure to express a sufficient number of glucose transporters in the plasma membrane (and T-system) of their skeletal muscles. Normally when insulin binds to its receptor on the cell surface, it initiates a chain of events that leads to the insertion in the plasma membrane of increased numbers of a transmembrane glucose transporter. This transporter forms a channel that permits the facilitated diffusion of glucose into the cell. Skeletal muscle is the major "sink" for removing excess glucose from the blood (and converting it into glycogen). In NIDDM, the patient's ability to remove glucose from the blood and convert it into glycogen is reduced. This is called insulin resistance. NIDDM (also called Type 2 diabetes mellitus) usually occurs in adults and, particularly often, in overweight people.
Alpha Cells
The alpha cells of the islets secrete glucagon, a polypeptide of 29 amino acids. Glucagon acts principally on the liver where it stimulates the conversion of glycogen into glucose (glycogenolysis) which is deposited in the blood.
Glucagon secretion is
stimulated by low levels of glucose in the blood;
inhibited by high levels, and
inhibited by amylin.
The physiological significance of this is that glucagon functions to maintain a steady level of blood sugar level between meals.
Delta Cells
The delta cells secrete somatostatin. Somatostatin has a variety of functions. Taken together, they work to reduce the rate at which food is absorbed from the contents of the intestine. Somatostatin is also secreted by the hypothalamus and by the intestine.
Gamma Cells
The gamma cells of the islets secrete pancreatic polypeptide. No function has yet been found for this peptide of 36 amino acids.
Classification On the basis of Receptors, drugs can be divided into four groups
Pharmacology
On the basis of Receptors, drugs can be divided into four groups,
a. agonists
b. antagonists
c. agonist-antagonists
d. partial agonists
a. Agonist
morphine fentanyl pethidine
Action : activation of all receptor subclasses, though, with different affinities
b. Antagonist
Naloxone , Naltrexone
Action : Devoid of activity at all receptor classes
c. Partial Agonist: (Mixed Narcotic Agonists/Antagonists)
Pentazocine, Nalbuphine, Butorphanol , Buprenorphine
Action: activity at one or more, but not all receptor types
With regard to partial agonists, receptor theory states that drugs have two independent properties at receptor sites,
a. affinity
The ability, or avidity to bind to the receptor
Proportional to the association rate constant, Ka
b. efficacy
or, intrinsic activity, and is the ability of the D-R complex to initiate a pharmacological effect
Drugs that produce a less than maximal response and, therefore, have a low intrinsic activity are called partial agonists.
These drugs display certain pharmacological features,
a. the slope of the dose-response curve is less than that of a full agonist
b. the dose response curve exhibits a ceiling with the maximal response below that obtainable by a full agonist
c. partial agonists are able to antagonise the effects of large doses of full agonists
Neuromuscular Blockers in Cardiac Anesthesia
General SurgeryNeuromuscular Blockers in Cardiac Anesthesia
In patient on β-blockers, the choice of neuromuscular
blockers (NMBs) is critical due to their potential cardiovascular effects.
Here’s a detailed analysis of the implications of using fentanyl and various
NMBs, particularly focusing on vecuronium and its effects.
Key Points on Fentanyl and β-Blockers
Fentanyl:
Fentanyl is an opioid analgesic that can cause bradycardia due to
its vagolytic activity. While it has minimal hemodynamic effects, the
bradycardia it induces can be problematic, especially in patients
already on β-blockers, which reduce heart rate and blood pressure.
β-Blockers:
These medications reduce heart rate and blood pressure, which can
compound the bradycardic effects of fentanyl. Therefore, careful
consideration must be given to the choice of additional medications that
may further depress cardiac function.
Vecuronium
Effects:
Vecuronium is a non-depolarizing neuromuscular blocker that has
minimal cardiovascular side effects when used alone. However, it can
potentiate decreases in heart rate and cardiac index when administered
after fentanyl.
The absence of positive chronotropic effects (unlike pancuronium)
means that vecuronium does not counteract the bradycardia induced by
fentanyl, leading to a higher risk of significant bradycardia and
hypotension.
Vagal Tone:
Vecuronium may enhance vagal tone, further predisposing patients to
bradycardia. This is particularly concerning in patients on β-blockers,
as the combination can lead to compounded cardiac depression.
Comparison with Other Neuromuscular Blockers
Pancuronium:
Vagolytic Action: Pancuronium has vagolytic
properties that can help attenuate bradycardia and support blood
pressure. It is often preferred in cardiac anesthesia for its more
favorable hemodynamic profile compared to vecuronium.
Tachycardia: While it can induce tachycardia, this
effect may be mitigated in patients on β-blockers, which can blunt the
tachycardic response.
Atracurium:
Histamine Release: Atracurium can release
histamine, leading to hemodynamic changes such as increased heart rate
and decreased blood pressure. These effects can be minimized by slow
administration of small doses.
Rocuronium:
Minimal Hemodynamic Effects: Rocuronium is
generally associated with a lack of significant cardiovascular side
effects, although occasional increases in heart rate have been noted.
Cis-Atracurium:
Cardiovascular Stability: Cis-atracurium does not
have cardiovascular effects and does not release histamine, making it a
safer option in terms of hemodynamic stability.
Rickettsial Diseases -Epidemic Typhus
General Pathology
Rickettsial Diseases
Epidemic Typhus
An acute, severe, febrile, louse-borne disease caused by Rickettsia prowazekii, characterized by prolonged high fever, intractable headache, and a maculopapular rash.
Symptoms, Signs, and Prognosis
After an incubation period of 7 to 14 days, fever, headache, and prostration suddenly occur. Temperature reaches 40° C (104° F) in several days and remains high, with slight morning remission, for about 2 wk. Headache is generalized and intense. Small pink macules appear on the 4th to 6th day, usually in the axillae and on the upper trunk; they rapidly cover the body, generally excluding the face, soles, and palms. Later the rash becomes dark and maculopapular; in severe cases, the rash becomes petechial and hemorrhagic. Splenomegaly occurs in some cases. Hypotension occurs in most seriously ill patients; vascular collapse, renal insufficiency, encephalitic signs, ecchymosis with gangrene, and pneumonia are poor prognostic signs. Fatalities are rare in children < 10 yr, but mortality increases with age and may reach 60% in untreated persons > 50 yr.
Antianginal Drugs-Adverse
PharmacologyAdverse effects
Nitrates
– Headache, hypotension, dizziness, lightheadedness, tachycardia, palpitations
Beta-adrenergic blocking agents
– hypotension, bradycardia, bronchospasm, congestive heart failure
Calcium channel blockers
– hypotension, dizziness, lightheadedness, weakness, peripheral edema, headache, congestive heart failure, pulmonary edema, nausea, and constipation
Drugs that increase effects of Antianginal drugs
• Antihypertensive
• Diuretics
• Phenothiazine antipsychotic agents
• Cimetidine
• Digoxin
Drugs that decrease effects of Antianginal
• Adrenergic drugs - epinephrine
• Anticholinergic
• Calcium salts
• Phenobarbital, Phenytoin
Adjunctive Antianginal Drugs
In addition to antianginal drugs, several other drugs may be used to control risk factors and prevent progression of myocardial ischemia to myocardial infarction and sudden cardiac death.
These may include:
• Aspirin. This drug has become the standard of care because of its antiplatelet (ie, antithrombotic) effects. Recommended doses vary from 81 mg daily to 325 mg daily or every other day; apparently all doses are beneficial in reducing the possibility of myocardial reinfarction, stroke, and death. Clopidogrel 75 mg/day,
Is an acceptable alternative for individuals with aspirin allergy.
• Antilipemics. These drugs may be needed by clients who are unable to lower serum cholesterol levels sufficiently with a low-fat diet. Lovastatin or a related “statin” is often used. The goal is usually to reduce the serum cholesterol level below 200 mg/dL and lowdensitylipoprotein cholesterol to below
130 mg/dL.
• Antihypertensives. These drugs may be needed for clients with hypertension. Because beta blockers and calcium channel blockers are used to manage hypertension as well as angina, one of these drugs may be effective for both disorders.
Trigeminal Neuralgia
Oral and Maxillofacial SurgeryTrigeminal Neuralgia
Trigeminal neuralgia (TN) is a type of orofacial neuralgia
characterized by severe, paroxysmal pain that follows the anatomical
distribution of the trigeminal nerve (cranial nerve V). It is often described as
one of the most painful conditions known, and understanding its features,
triggers, and patterns is essential for effective management.
Features of Trigeminal Neuralgia
Anatomical Distribution:
Trigeminal neuralgia follows the distribution of the trigeminal
nerve, which has three main branches:
V1 (Ophthalmic): Supplies sensation to the
forehead, upper eyelid, and parts of the nose.
V2 (Maxillary): Supplies sensation to the
cheeks, upper lip, and upper teeth.
V3 (Mandibular): Supplies sensation to the
lower lip, chin, and lower teeth.
Pain can occur in one or more of these dermatomes, but it is
typically unilateral.
Trigger Zones:
Patients with trigeminal neuralgia often have specific trigger
zones on the face. These are areas where light touch, brushing,
or even wind can provoke an episode of pain.
Stimulation of these trigger zones can initiate a paroxysm of pain,
leading to sudden and intense discomfort.
Pain Characteristics:
The pain associated with trigeminal neuralgia is described as:
Paroxysmal: Occurs in sudden bursts or attacks.
Excruciating: The pain is often severe and
debilitating.
Sharp, shooting, or lancinating: Patients may
describe the pain as electric shock-like.
Unilateral: Pain typically affects one side of
the face.
Intermittent: Attacks can vary in frequency and
duration.
Latency and Refractory Period:
Latency: This refers to the short time interval
between the stimulation of the trigger area and the onset of pain. It
can vary among patients.
Refractory Period: After an attack, there may be a
refractory period during which further stimulation does not elicit pain.
This period can vary in length and is an important aspect of the pain
cycle.
Pain Cycles:
Paroxysms of pain often occur in cycles, with each cycle lasting for
weeks or months. Over time, these cycles may become more frequent, and
the intensity of pain can increase with each attack.
Patients may experience a progressive worsening of symptoms, leading
to more frequent and severe episodes.
Psychosocial Impact:
The unpredictable nature of trigeminal neuralgia can significantly
impact a patient's quality of life, leading to anxiety, depression, and
social withdrawal due to fear of triggering an attack.
Management of Trigeminal Neuralgia
Medications:
Anticonvulsants: Medications such as carbamazepine
and oxcarbazepine are commonly used as first-line treatments to help
control pain.
Other Medications: Gabapentin, pregabalin,
and baclofen may also be effective in managing symptoms.
Surgical Options:
For patients who do not respond to medication or experience
intolerable side effects, surgical options may be considered. These can
include:
Microvascular Decompression: A surgical
procedure that relieves pressure on the trigeminal nerve.
Rhizotomy: A procedure that selectively
destroys nerve fibers to reduce pain.
Alternative Therapies:
Some patients may benefit from complementary therapies such as
acupuncture, physical therapy, or biofeedback.
Bones of the Skull
Anatomy
BONES OF THE CRANIUM
Occipital (1)
Frontal (1)
Sphenoid (1)
Ethmoid (1)
Parietal (2)
Temporal (2)
BONES OF THE FACE
Mandible (1)
Vomer (1)
Maxillae (2)
Zygomae (2)
Lacrimal (2)
Nasal (2)
Inferior nasal conchae (2)
Palatine (2)
PERIOTEST Device in Periodontal Assessment
PeriodontologyPERIOTEST Device in Periodontal
Assessment
The PERIOTEST device is a valuable tool used in dentistry to assess the
mobility of teeth and the reaction of the periodontium to applied forces. This
lecture covers the principles of the PERIOTEST device, its measurement scale,
and its clinical significance in evaluating periodontal health.
Function: The PERIOTEST device measures the reaction
of the periodontium to a defined percussion force applied to the tooth. This is
done using a tapping instrument that delivers a controlled force to the tooth.
Contact Time: The contact time between the tapping
head and the tooth varies between 0.3 and 2 milliseconds. This duration is
typically shorter for stable teeth compared to mobile teeth, allowing for a
quick assessment of tooth stability.
PERIOTEST Scale
The PERIOTEST scale ranges from -8 to +50, with specific ranges
indicating different levels of tooth mobility:
Readings
Inference
-8 to 9
Clinically firm teeth
10 to 19
First distinguishable sign of movement
20 to 29
Crown deviates within 1 mm of its normal position
30 to 50
Mobility is readily observed
Clinical Significance
Assessment of Tooth Mobility:
The PERIOTEST device provides a quantitative measure of tooth mobility,
which is essential for diagnosing periodontal disease and assessing the
stability of teeth.
Correlation with Other Measurements:
The PERIOTEST values correlate well with:
Tooth Mobility Assessed with a Metric System: This allows
for a standardized approach to measuring mobility, enhancing the reliability
of assessments.
Degree of Periodontal Disease and Alveolar Bone Loss:
Higher mobility readings often indicate more severe periodontal disease and
greater loss of supporting bone, making the PERIOTEST a useful tool in
monitoring disease progression.
Treatment Planning:
Understanding the mobility of teeth can aid in treatment planning,
including decisions regarding periodontal therapy, splinting of mobile teeth, or
extraction in cases of severe mobility.